



Supplemental Digital Content 1. The fraction (%) of HIV patients with VL ≥ 50 copies/ml stratified on gender and route of transmission. Broken lines: HIV patients on single-tablet regimen including tenofovir, efavirenz and emtricitabine (STR-TEE) for >1 year per 1 April, 2010 who continued STR-TEE. Full line: HIV patients on STR-TEE >1 year, who were switched from to triple-table regimen including tenofovir, efavirenz and lamivudine (TTR-TEL) after 1 April 2011.





Supplemental Digital Content 2.

The prizes for a defined daily dose (DDD) of single-tablet regimen including tenofovir, efavirenz and emtricitabine (STR-TEE) and triple-table regimen including tenofovir, efavirenz and lamivudine (TTR-TEL) 2010 and 2011. The DDD prize difference between STR-TEE and TTR-TEL was \$8.9 in 2011.

	Prizes per DDD 2010	Prizes per DDD 2011
Fixed-dose tablet of emtricitabine, tenofovir and efavirenz	\$41.6	\$43.7
Lamivudine	\$7.2	\$7.5
Tenofovir	\$17.4	\$17.7
Efavirenz	\$11.9	\$9.6
Total cost of triple-tablet regimen including lamivudine, tenofovir and efavirenz	\$36.5	\$34.8
Difference	\$5.1	\$8.9